# Andy Walker

> Andy Walker is a chemical engineer turned biotech operator who co-founded GentiBio, a Cambridge-based company engineering regulatory T cells (EngTregs) to functionally cure autoimmune and autoinflammatory diseases. He started as the company's CTO, moved through President and COO, and became President and CEO in 2024. Before GentiBio he ran manufacturing for cell and protein therapeutics at Juno Therapeutics and led Jewel Biotherapeutics. He holds a PhD in chemical engineering from UC Berkeley and a BS from the University of Washington.

- **Role:** Co-founder, President and CEO at GentiBio
- **Organizations:** GentiBio, Jewel Biotherapeutics, Juno Therapeutics, AGC Biologics
- **Nationality:** American
- **Education:** Ph.D. in Chemical Engineering, University of California, Berkeley, B.S. in Chemical Engineering, University of Washington
- **Known for:** Co-founded GentiBio, a regulatory T cell therapy company, Helped raise more than $177M in total funding across seed and Series A rounds, Advanced engineered Treg (EngTreg) platform toward the clinic, including GNTI-122 for type 1 diabetes

## Career timeline

- **2020** — Co-founded GentiBio with Adel Nada and Chandra Patel; served as Chief Technology Officer
- **2020** — GentiBio launched with $20M seed funding and licensing deals with Seattle Children's, BRI and MIGAL
- **2021** — GentiBio raised a $157M Series A led by Matrix Capital Management
- **2022** — GentiBio entered a cell therapy collaboration with Bristol Myers Squibb
- **2024** — Named President and CEO of GentiBio after serving as President and COO

## Achievements

- Co-founded GentiBio, a regulatory T cell therapy company
- Helped raise more than $177M in total funding across seed and Series A rounds
- Advanced engineered Treg (EngTreg) platform toward the clinic, including GNTI-122 for type 1 diabetes
- Previously led GMP manufacturing of cellular and protein therapeutics as SVP of Technical Operations at Juno Therapeutics
- Served as CEO of Jewel Biotherapeutics

## Latest updates

- **2024** — Became President and CEO of GentiBio
- **2026** — GentiBio's lead EngTreg asset GNTI-122 for type 1 diabetes progressing with clinical readouts anticipated

## Links

- Website: https://gentibio.com
- LinkedIn: http://www.linkedin.com/in/andy-walker-a884a03

---

Profile page: https://yespress.io/andy-walker
Published by YesPress — https://yespress.io
Last updated: 2026-06-14